Lincoln, Nebraska, 68502, United States
NCT Number: NCT01924143
TD-9855 Mass Balance Study
The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy, nonsmoking male subjects or healthy, nonsmoking female subjects not of childbearing potential, 18 to 50 years old, inclusive. Women are considered to be not of childbearing potential if they have had a hysterectomy or tubal ligation or are at least 2 years postmenopausal (follicle-stimulating hormone [FSH] >40 IU/mL)
- Body mass index 19 to 31 kg/m2, inclusive, and weight at least 55 kg
- Negative for hepatitis B, hepatitis C, and HIV antibody
Exclusion criteria
- Have evidence or history of clinically significant allergic (except for untreated, asymptomatic, seasonal allergies at time of dosing), hematological, endocrine, dermatologic, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease
- Subjects who, in the opinion of the investigator, are at risk for suicide or risk of harming others, or who score positive on the C-SSRS (item 2 or higher on ideation). Subjects with any history of suicide attempts
- Any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas])
- Infrequent bowel movements (less than once per 24 hours) in the last 7 days prior to Day -1. Subject is unable to provide a fecal sample prior to study drug dosing on Day -1 or Day 1.
Treatment and study plan
TD-9855
Drugradiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)
Primary outcomes
-
To define the routes and rates of elimination and mass balance of [14C]-labeled TD-9855
Time frame: 1-21 Days
Urinary and fecal recovery of total radioactivity. Whole blood and plasma concentrations of total radioactivity.
Secondary outcomes
-
Pharmacokinetics of total drug-related material and TD-9855: Cmax
Time frame: 1-21 Days
Whole blood and plasma concentrations
-
PK: Tmax
Time frame: 1-21 Days
Whole blood and plasma concentrations
-
PK: AUCt
Time frame: 1-21 Days
Whole blood and plasma concentrations
-
PK: AUCinf
Time frame: 1-21 Days
-
PK: CL/F (Renal clearance)
Time frame: 1-21 Days
Urine
-
PK: Vz/F (oral volume of distribution during the terminal phase)
Time frame: 1-21 Days
-
PK: amount excreted in urine (Ae)
Time frame: 1-21 Days
Urine
-
PK: CLR (Renal clearance, computed as amount recovered in urine/ AUCinf)
Time frame: 8-21 Days
Urine
-
Metabolic profiles in plasma and excreta
Time frame: 1-21 days
Sponsors and collaborators
Lead sponsor
Theravance Biopharma
Industry
Registry information
Official study title
An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 µCi [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects
Important dates
- Study start
- 2013
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Aug 16, 2013
- Registry last updated
- Jan 19, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
NCT04095377
ABD, ADHD
Rishon LeZiyyon, Israel
View Trial DetailsCharacterization of the DELPhI System in Assessing Brain's Functionality in Different Neurological Disorders
NCT03832413
ABD, ADHD
Rishon LeZiyyon, Israel
View Trial DetailsEvaluating Stress Management Strategies Within the School Readiness Parenting Program
NCT06626750
ADHD, Attention Deficit Disorder with Hyperactivity
Miami, Florida, United States
View Trial DetailsReducing Disparities in Behavioral Health Treatment for Children in Primary Care
NCT04082234
ADHD, Attention Deficit Disorder with Hyperactivity
Philadelphia, Pennsylvania, United States
View Trial Details